What is it about?
non-small cell lung cancer (NSCLC) is a lethal cancer, which is difficult to treat, Epigentic therapy is one of candidate effective therapy which its target is unknown. In this study, using integrated analysis of gene expression and promoter methylation in reprogrammed NSCLC cell lines, we identify SFRP1 as a potencial therapy target.
Featured Image
Why is it important?
Although epigentic therapy was known to be an effective treatment of NSCLC, it was unknown which genes were targeted. In this study, SFRP1 turned out to be a potential target.
Perspectives
Recently, I proposed principal component analysis based unsupervised feature extraction applied to various bioinformatic analyses. It is a one of papers where this methodology was successfully applied.
Professor Y-h. Taguchi
Chuo Daigaku
Read the Original
This page is a summary of: SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer, BMC Medical Genomics, August 2016, Springer Science + Business Media,
DOI: 10.1186/s12920-016-0196-3.
You can read the full text:
Resources
Contributors
The following have contributed to this page
